Stem Cell Therapeutics Corp. Announces Enrollment of the First Patient in its REGENESIS Phase IIb Stroke Trial
CALGARY, ALBERTA, May 28, 2008 (MARKET WIRE via COMTEX) ----Stem Cell Therapeutics Corp. ("SCT") (TSX VENTURE: SSS) is pleased to announce the enrollment of the first patient in its REGENESIS Phase IIb stroke trial. The REGENESIS trial is a double-blind, randomized, placebo-controlled Phase IIb clinical trial for SCT's lead program, NTx-265, for the treatment of acute ischemic stroke.
The company's programs aim to repair neurological function lost due to disease or injury. The company's extensive patent portfolio of owned and licensed intellectual property supports the potential expansion into future clinical programs in numerous neurological diseases such as traumatic brain injury and multiple sclerosis.
Israeli Scientists Recipients of 2008 International Adult Stem Cell Award
According to Donald Margolis, WCASCE Chairman and Founder, "Professor Slavin is an expert bone marrow transplantation scientist and clinician. The former Director of Israel's National Stem Cell Transplantation Center at Hadassah before establishing the ICTC, Prof. Slavin will soon be among the few experts who also treat bone repair and reconstruction of cartilage in addition to innovative clinical application of stem cells and cell-mediated immunotherapy for the treatment of hematological malignancies, solid tumors and a broad spectrum of non-malignant disorders treatable by stem cell transplantation. Professors Slavin and Karussis' team are the first in the world to try and help multiple sclerosis and amyotropic lateral sclerosis patients by injecting their spinal fluid with large numbers of adult stem cells (mesenchymal stromal stem cells) taken from their bone marrow and multiplied in culture. Some of the patients' conditions have improved or stabilized in Phase I and II clinical trials."